Cellectis and Thermo Fisher Scientific have entered into a series of agreements for the use of TAL nucleases under the brand name TALEN. Commercial terms were not disclosed.   Thermo Fisher will have rights to the TAL nucleases with exclusive rights to grant R&D, bioproduction, and certain applied markets, where Thermo currently markets TALEN for these applications. Cellectis will have a worldwide license under Thermo Fisher’s rights to TAL nucleases in the R&D field for internal and col...